PSIL
AdvisorShares Psychedelics ETF
Price Chart
Latest Quote
$20.09
| Previous Close | $19.83 |
| Open | $20.15 |
| Day High | $20.10 |
| Day Low | $19.46 |
| Volume | 15,724 |
Fund Information
| Quarterly Dividend / Yield | N/A / 7.95% |
| Net Assets | $36.70M |
| Expense Ratio | 1.00% |
| Category | Miscellaneous Sector |
| Fund Family | AdvisorShares |
| Net Asset Value | $19.96 |
| Premium/Discount | 0.63% |
| Quarterly Dividend Yield | 7.95% |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $20.38 |
| SMA50 | $19.91 |
| SMA200 | $17.78 |
| RSI | 37.54 |
| ATR | 0.8194 |
| Rel Volume | 0.54 |
Performance History
| Week | +1.72% |
| Month | +4.28% |
| Quarter | +21.98% |
| 6 Months | +12.93% |
| YTD | +16.80% |
| Year | +55.37% |
| 3 Years | +26.49% |
| 10 Years | -76.61% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $20.09 | 15,700 |
| 2026-06-17 | $19.83 | 6,300 |
| 2026-06-16 | $19.58 | 9,800 |
| 2026-06-15 | $19.29 | 22,500 |
| 2026-06-12 | $20.16 | 13,700 |
| 2026-06-11 | $19.75 | 23,500 |
| 2026-06-10 | $19.24 | 23,300 |
| 2026-06-09 | $19.51 | 19,600 |
| 2026-06-08 | $19.20 | 30,900 |
| 2026-06-05 | $19.70 | 38,500 |
| 2026-06-04 | $20.84 | 20,000 |
| 2026-06-03 | $20.63 | 51,400 |
| 2026-06-02 | $21.17 | 33,400 |
| 2026-06-01 | $21.94 | 82,000 |
| 2026-05-29 | $21.72 | 35,100 |
| 2026-05-28 | $21.46 | 34,300 |
| 2026-05-27 | $20.90 | 20,600 |
| 2026-05-26 | $21.11 | 43,500 |
| 2026-05-22 | $21.13 | 38,600 |
| 2026-05-21 | $20.45 | 17,900 |
| 2026-05-20 | $19.87 | 28,000 |
| 2026-05-19 | $19.26 | 34,100 |
About AdvisorShares Psychedelics ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
